A Triple-Combined Strategy Surpassing the Limits of Tuberculosis Treatment: Nanocarriers, Host Modulation, and Translational Pharmacology
##1. The Fortress of Mycobacterium tuberculosis: Pathological Barriers of Granulomas and Intracellular Parasitism Tuberculosis (TB) is one of the deadliest infectious diseases in human history, and the pathogen Mycobacterium tuberculosis employs a unique mechanism to survive within host macrophages without being killed. In particular, the physical barrier formed at the site of infection, the granuloma, impedes penetration of conventional antibiotics, extending treatment duration to more than six months, which in turn reduces patient adherence and creates a vicious cycle leading to the emergence of multidrug‑resistant (MDR) and extensively drug‑resistant (XDR) TB.
##2. Nanoplatforms: Nano‑Scale Trojan Horses that Penetrate Granuloma Barriers The research team proposes using various nanocarriers such as polymeric nanoparticles, liposomes, and dendrimers to maximize drug delivery efficiency. Notably, biomimetic membrane‑coated systems evade host cellular surveillance and reach the target site, while inhalable formulations deliver drugs directly to lung tissue and deep within granulomas. These nanotechnologies provide a technical foundation that maintains therapeutic concentrations at the target while lowering systemic drug levels, thereby dramatically reducing systemic side effects.
##3. Host‑Directed Therapy (HDT): Immune Re‑engineering that Trains the Host Rather Than the Pathogen The innovation of this strategy lies in Host‑Directed Therapy, which precisely modulates the host immune response instead of directly attacking the pathogen. By forcibly activating autophagy or reprogramming macrophages to self‑degrade the bacteria, and by leveraging miRNA regulation and antimicrobial peptide pathways to boost immunity, this approach avoids targeting bacterial proteins or enzymes, thereby fundamentally circumventing antibiotic resistance mechanisms.
##4. Incorporation of Translational Pharmacology: Bridging the Laboratory and Clinic for Personalized Precision Medicine The ultimate vision presented by this study is the integration of nanotechnology, immunology, and Translational Pharmacology. Receptor‑mediated active targeting technologies enable modulation of drug release rate and location according to patient condition, while optimized manufacturing processes ensure scalability. This transforms tuberculosis treatment from simple “antibiotic administration” to a combination of intelligent delivery systems and immune optimization, heralding a new era that simultaneously shortens treatment duration and improves cure rates.
TB remains a significant global health burden due to protracted therapeutic courses, poor patient compliance, and toxicities associated with drug treatment, as well as concerns arising from increasingly prevalent multidrug-resistant and extensively drug-resistant strains of M. tuberculosis. The escalating prevalence of multidrug-resistant and extensively drug-resistant strains, compounded by the pathogen's extraordinary capacity to survive within host macrophages and pharmacologically impenetrable granulomas, has rendered conventional chemotherapy progressively insufficient, exposing an urgent and unmet need for transformative therapeutic innovation. This review comprehensively addresses that need by critically examining three converging paradigms redefining tuberculosis management: nanocarrier-based drug delivery systems, host-directed therapeutic strategies, and translational pharmacology. We systematically evaluate the structural and molecular determinants of Mycobacterium tuberculosis underpinning drug resistance and intracellular persistence, alongside an in-depth analysis of diverse nanocarrier platforms-polymeric nanoparticles, liposomes, solid lipid nanocarriers, dendrimers, biomimetic membrane-coated systems, and inhalable formulations, and host-directed approaches targeting autophagy, macrophage reprogramming, miRNA regulation, and antimicrobial peptide pathways. Receptor-mediated active targeting strategies, translational pharmacology frameworks, manufacturing challenges, and regulatory barriers are critically appraised, with an emerging roadmap encompassing artificial intelligence, CRISPR genomics, and mRNA-LNP vaccine platforms. This review equips researchers, clinicians, and pharmaceutical scientists with an integrated, evidence-based framework to accelerate the development and clinical translation of next-generation anti-tuberculosis therapeutics, ultimately contributing to the global ambition of ending tuberculosis.
This study completely shifts the paradigm of tuberculosis treatment from a 'Pathogen‑centric' to a 'Host & Delivery‑centric' approach. By combining nanotechnology‑mediated overcoming of physical barriers with immune re‑engineering to evade resistance, it provides a concrete methodology that dramatically shortens the long‑standing tuberculosis treatment guidelines and enables the implementation of precision medicine, representing a uniquely significant scholarly contribution.